Nociceptin Receptor (NOP) Neurons

Nociceptin Receptor (NOP) Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Nociceptin Receptor (NOP) Neurons</th>
</tr>
<tr>
<td class="label">Receptor Name</td>
<td>Nociceptin Receptor (NOP/OPRL1)</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>Nociceptin/Orphanin FQ (N/OFQ)</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>OPRL1</td>
</tr>
<tr>
<td class="label">G Protein</td>
<td>Gi/o (inhibitory)</td>
</tr>
<tr>
<td class="label">Primary Location</td>
<td>Cortex, Hippocampus, Amygdala, Spinal Cord</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Gi/o protein</td>
<td>Inhibits adenylate cyclase, reduces cAMP</td>
</tr>
<tr>
<td class="label">MAPK cascades</td>
<td>ERK1/2, p38, JNK activation</td>
</tr>
<tr>
<td class="label">Ion channels</td>
<td>Activates GIRKs, inhibits VGCCs</td>
</tr>
<tr>
<td class="label">Beta-arrestin</td>
<td>Mediates receptor internalization</td>
</tr>
</table>

Nociceptin Receptor (NOP) Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Nociceptin Receptor (NOP) Neurons</th>
</tr>
<tr>
<td class="label">Receptor Name</td>
<td>Nociceptin Receptor (NOP/OPRL1)</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>Nociceptin/Orphanin FQ (N/OFQ)</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>OPRL1</td>
</tr>
<tr>
<td class="label">G Protein</td>
<td>Gi/o (inhibitory)</td>
</tr>
<tr>
<td class="label">Primary Location</td>
<td>Cortex, Hippocampus, Amygdala, Spinal Cord</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Gi/o protein</td>
<td>Inhibits adenylate cyclase, reduces cAMP</td>
</tr>
<tr>
<td class="label">MAPK cascades</td>
<td>ERK1/2, p38, JNK activation</td>
</tr>
<tr>
<td class="label">Ion channels</td>
<td>Activates GIRKs, inhibits VGCCs</td>
</tr>
<tr>
<td class="label">Beta-arrestin</td>
<td>Mediates receptor internalization</td>
</tr>
</table>

Nociceptin Receptor (Nop) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Nociceptin Receptor (NOP) neurons express the nociceptin/orphanin FQ (N/OFQ) peptide receptor, also known as the opioid receptor-like 1 (OPRL1). These neurons constitute a distinct neuromodulatory system involved in pain transmission, reward processing, anxiety, learning, and neuroendocrine control. [@witkin2014]

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Molecular Biology

Receptor Structure

The NOP receptor is a Class A G protein-coupled receptor (GPCR) with:

• Seven transmembrane domains
• N-terminal extracellular domain involved in ligand binding
• C-terminal intracellular domain for G protein coupling
• Multiple splice variants with distinct pharmacological profiles

Signal Transduction

NOP receptor activation triggers multiple intracellular pathways:

Ligand: Nociceptin/Orphanin FQ

Nociceptin is a 17-amino acid neuropeptide structurally related to dynorphin A but with distinct pharmacological properties:

• Precursor: Prepronociceptin (PNOC) gene
• Post-translational processing: Produces N/OFQ and related peptides
• Distribution: Widespread in CNS and peripheral nervous system
• Physiological roles: Pain modulation, reward, anxiety, learning, memory

Anatomical Distribution

Forebrain

Cerebral Cortex:

• Layer II/III pyramidal neurons: High NOP expression
• Layer V corticotegmental neurons: Moderate expression
• Parvalbumin+ interneurons: NOP present in some subpopulations
• Functions: Cortical plasticity, sensory processing

• CA1 pyramidal cells: NOP modulates synaptic plasticity
• CA3 pyramidal cells: Involved in memory consolidation
• Dentate gyrus granule cells: Regulation of neurogenesis
• Hippocampal interneurons: NOP inhibits GABA release
• Role in neurodegeneration: NOP dysregulation contributes to memory deficits in AD

• Central nucleus: High NOP density, anxiety regulation
• Basolateral amygdala: Emotional memory processing
• Bed nucleus of the stria terminalis: Stress responses
• Role in neurodegeneration: NOP alterations in AD and PD

• Striatum: Modulates dopaminergic signaling
• Substantia nigra pars compacta: NOP affects dopamine neuron survival
• Globus pallidus: Motor control functions
• Role in PD: NOP agonists may protect dopamine neurons

Brainstem

Raphe Nuclei:

• Dorsal raphe: Mood regulation
• Median raphe: Anxiety-related behaviors
• NOP modulates serotonergic transmission

• Noradrenergic neurons express NOP
• Nociceptin reduces norepinephrine release
• Role in AD: LC noradrenergic degeneration is early event

• NOP in pain modulation circuits
• Involved in descending pain inhibition

Spinal Cord

• Dorsal horn: NOP on primary afferents and interneurons
• Lamina I-II: Nociceptin reduces pain transmission
• Motor neurons: NOP effects on spinal motor circuits
• Clinical relevance: NOP agonists as analgesic agents

Functions and Physiology

Pain Modulation

NOP neurons exhibit bidirectional pain modulatory effects:

Peripheral Analgesia:

• NOP agonists produce analgesia at peripheral sites
• Effective in inflammatory and neuropathic pain models
• Limited abuse potential compared to traditional opioids

• NOP activation inhibits substance P release
• Reduces dorsal horn neuron excitability
• Synergistic effects with mu-opioid receptor agonists

• Complex effects on pain perception
• Nociceptin can produce both analgesic and pro-nociceptive effects
• Context-dependent actions based on brain region

Reward and Motivation

The NOP system interacts with mesolimbic dopamine pathways:

• VTA dopamine neurons: NOP modulates firing rate
• Nucleus accumbens: N/OFQ reduces reward-seeking behavior
• Prefrontal cortex: Affects decision-making and impulsivity
• Clinical relevance: NOP antagonists as potential antidepressants

Anxiety and Emotional Processing

• Anxiogenic effects: Nociceptin administration increases anxiety
• Amygdala function: NOP regulates fear and anxiety responses
• Stress response: N/OFQ released during stress
• Potential therapy: NOP antagonists for anxiety disorders

Learning and Memory

• Hippocampal plasticity: NOP modulates LTPmechanisms/long-term-potentiation) and LTD
• Memory consolidation: N/OFQ affects recall
• Spatial learning: NOP in place cell function
• Neurodegeneration: NOP alterations in AD models

Neuroendocrine Control

• Hypothalamic regulation: NOP affects pituitary hormone release
• CRH/ACTH: N/OFQ modulates stress axis
• Growth hormone: NOP influences GH secretion
• Prolactin: N/OFQ effects on prolactin release

Clinical Significance in Neurodegeneration

Alzheimer's Disease

NOP System Alterations:

• NOP receptor binding reduced in AD hippocampus
• N/OFQ levels elevated in CSF of AD patients
• Correlation with cognitive decline severity

• NOP dysregulation contributes to memory impairment
• Interactions with amyloid-beta pathology
• Effects on tau phosphorylation

• NOP agonists: Memory enhancement potential
• NOP antagonists: May reduce amyloid toxicity
• Clinical trials ongoing

Parkinson's Disease

NOP Involvement:

• NOP receptors on dopaminergic neurons
• N/OFQ neuroprotective effects in PD models
• NOP agonists reduce levodopa-induced dyskinesias

• NOP modulation as adjunct to dopaminergic therapy
• Neuroprotection in early PD
• Motor complication management

Amyotrophic Lateral Sclerosis (ALS)

• NOP system alterations in ALS models
• Motor neuron vulnerability and NOP
• Potential therapeutic targeting

Other Neurodegenerative Conditions

• Huntington's Disease: NOP in basal ganglia dysfunction
• Frontotemporal Dementia: NOP in emotional processing
• Multiple System Atrophy: Autonomic function modulation

Therapeutic Targeting

NOP Agonists

Clinical Candidates:

• SCH-221510: NOP agonist, analgesic development
• Ro64-6198: NOP agonist, anxiety/pain
• MCOPPB: Potent NOP agonist

• Chronic pain management
• Parkinson's disease (neuroprotection)
• Addiction treatment (reduce reward)
• Pruritus (itch)

NOP Antagonists

Clinical Candidates:

• SB-612111: NOP antagonist
• J-113397: Selective NOP antagonist
• LY2940094: NOP antagonist, depression

• Depression and anxiety
• Alcohol use disorder
• Cognitive enhancement in AD
• Weight management

Background

The study of Nociceptin Receptor (Nop) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Pathway Diagram

The following diagram shows the key molecular relationships involving Nociceptin Receptor (NOP) Neurons discovered through SciDEX knowledge graph analysis: